ArticleEuropean journal of heart failure2025
Clustering in dilated cardiomyopathy at initial evaluation: An effective tool for clinical stratification.
Article in European journal of heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Machine learning and multi-omics technologies for precision cardiovascular medicine: advancing diagnosis, risk prediction, and therapeutic guidance.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
aimsDilated cardiomyopathy (DCM) has a highly variable presentation and disease course. Current stratification strategies are complex and require multimodality evaluation. Using machine learning (ML) on a large dataset obtained at first cardiological evaluation, this study aims to identify specific DCM subgroups. METHODS AND
resultsIn a retrospective cohort of DCM patients, baseline clinical, genetic, and outcome data were collected. Unsupervised clustering was performed and then simplified to identify patient subgroups. The subgroups were characterized based on outcomes, including all-cause mortality/heart transplantation (HT)/left ventricular assist device implantation (LVAD), sudden cardiac death/major ventricular arrhythmias (SCD/MVA) and heart failure-related death/HT/LVAD. These findings were then validated in an external population. In the derivation cohort of 409 patients (mean age 46 ± 14 years, 71% male), two cluster-subgroups were identified: CL1 (82%) and CL2 (18%), mainly differentiated by electrocardiogram (ECG) characteristics. A lower yield of pathogenic/likely pathogenic variants was found in CL2 versus CL1 (15% vs. 47%, p < 0.001). A simplified clustering using only three variables (QRS duration, presence of left bundle branch block, intrinsicoid deflection >50 ms) was equally effective and validated in the external cohort of 160 patients (mean age 54 ± 13 years, 68% male). A lower risk for SCD/MVA events was observed for CL2 in the primary (hazard ratio 0.29, 95% confidence interval 0.13-0.67) and validation cohort (p = 0.017).
conclusionsUsing ML, baseline ECG variables were found to effectively identify two DCM subgroups differing in disease progression and genetic background. This approach could serve as a valuable tool for improving risk stratification of DCM patients upon their initial evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.